Filing Flows › Crispr Therapeutics AG (CRSP) › Q2 2026
Crispr Therapeutics AG (CRSP) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 3, 2026
Crispr Therapeutics AG (CRSP) reported revenue of $10.2M for the second quarter 2026 (Q2 2026), up 11-fold from a year earlier and +598% from the quarter before.
Crispr Therapeutics AG, Q2 2026: revenue $10.2M (11× year over year), net loss $91.2M, operating cash flow −$83.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.2M | +598% | 11× |
| Operating profit | −$117M | — | — |
| Net earnings | −$91.2M | — | — |
| Operating cash flow | −$83.5M | — | — |
What changed
Revenue was $10.2M in Q2 2026, up 1041% year over year and up 598% from the previous quarter. Collaboration Revenue was the largest line at 98% of revenue. Grant declined 80%.
Operating costs exceeded revenue by $117.3M, an operating margin of -1151.8%. Total costs fell 45% while revenue rose 1041%. The quarter ended with a net loss of $91.2M, narrower than the previous quarter's $122.9M loss. Non-operating items added $27.1M, -30% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$83.5M. Non-cash charges added back $4.3M of depreciation and amortization and $17.3M of share-based compensation. Working capital and other items used $13.9M. Capital expenditures of $648K exceeded it, leaving free cash flow of −$84.1M.
Questions
What was Crispr Therapeutics AG's revenue in the second quarter 2026?
Crispr Therapeutics AG (CRSP) reported revenue of $10.2M for the second quarter 2026 (Q2 2026), up 11-fold from a year earlier and +598% from the quarter before.